Evolus Reports Q1 2026 Earnings and Strategic Updates
Evolus, Inc. reported positive adjusted EBITDA for the second consecutive quarter in a seasonally low period due to cost improvements implemented in 2025. The company maintained its U.S. market share of Jeuveau at 14% despite new competition and plans FDA approval for Sculp by Q4 2026.
Topics: adjusted EBITDA AI integration digital ecosystem FDA approval outlook market share product strategy